Track D

D4 Riding the Regenerative Medicine Commercialization Wave

Track: Licensing Successful Practices

Target Audience: Intermediate

Mark Taylor, University Health Network

Ainslie Little, Torys LLP
Jennifer Moody, CCRM
Eric Soller, Versant Ventures

The gene- and cell-based platforms and therapeutic technologies which are being developed in the Regenerative Medicine (RM) field are so complex that it’s really no surprise that innovation is being led by universities, hospitals and research institutions. This requires the technology transfer community to be on top of its game in order to harness, protect and license inventors’ work plus plan for follow-on development. A deeper understanding of the RM patent, deal-making and industry partnership landscape is key to commercializing RM inventions. In this session, we will discuss trends and experiences in the RM commercialization space, both generally and with a special focus on several specific therapy classes including Chimeric Antigen Receptor (CAR) T-Cell therapies. The goal is to provide a critical overview of relevant commercial developments and practical guidance for technology transfer offices operating in the RM space with views from venture capital, industry, translation centers and patent strategy experts.

Return to Schedule

AUTM 2017 Annual Meeting Sponsors